tiprankstipranks
Advertisement
Advertisement

PRAX Stock Latest News

Praxis Precision price target raised to $462 from $449 at RBC Capital
The FlyPraxis Precision price target raised to $462 from $449 at RBC Capital
1d ago
PRAX
Praxis Precision price target raised to $514 from $400 at Baird
PremiumThe Fly
Praxis Precision price target raised to $514 from $400 at Baird
1d ago
PRAX
Praxis Precision price target raised to $362 from $323 at Wells Fargo
PremiumThe Fly
Praxis Precision price target raised to $362 from $323 at Wells Fargo
1d ago
PRAX
Praxis Precision Medicines Reaffirmed With Buy Rating on FDA Progress and $1.4 Billion Cash Runway Supporting 2028 Launch Plans
PremiumRatings
Praxis Precision Medicines Reaffirmed With Buy Rating on FDA Progress and $1.4 Billion Cash Runway Supporting 2028 Launch Plans
1d ago
PRAX
Praxis Precision reports Q2 EPS ($2.87), consensus ($3.69)
PremiumThe Fly
Praxis Precision reports Q2 EPS ($2.87), consensus ($3.69)
2d ago
PRAX
Praxis Highlights Strong Q2 Update and FDA Progress
PremiumCompany AnnouncementsPraxis Highlights Strong Q2 Update and FDA Progress
2d ago
8K
PRAX
Praxis Extends Vormatrogine Epilepsy Trial, Keeping Long-Term Growth Story in Play
Premium
Company Announcements
Praxis Extends Vormatrogine Epilepsy Trial, Keeping Long-Term Growth Story in Play
5d ago
PRAX
Praxis Advances PRAX-628 Tablet Formulation in Completed Bioavailability Study
Premium
Company Announcements
Praxis Advances PRAX-628 Tablet Formulation in Completed Bioavailability Study
5d ago
PRAX
Praxis Precision initiated with a Buy at Goldman Sachs
PremiumThe Fly
Praxis Precision initiated with a Buy at Goldman Sachs
26d ago
PRAX
Praxis Precision, Remagine Labs Partner on Ulixacaltamide Patch
PremiumCompany Announcements
Praxis Precision, Remagine Labs Partner on Ulixacaltamide Patch
1M ago
8K
PRAX
Praxis Precision, Remagine Labs announce research collaboration and license pact
PremiumThe Fly
Praxis Precision, Remagine Labs announce research collaboration and license pact
1M ago
PRAX
Raymond James Analyst Maintains Buy on Praxis, Sees PDUFA Extension as Manageable While Trimming Price Target from $731 to $719
PremiumRatings
Raymond James Analyst Maintains Buy on Praxis, Sees PDUFA Extension as Manageable While Trimming Price Target from $731 to $719
1M ago
PRAX
FDA Extends Review Timeline for Praxis’ Relutrigine NDA
PremiumCompany AnnouncementsFDA Extends Review Timeline for Praxis’ Relutrigine NDA
1M ago
8K
PRAX
Praxis Precision price target raised to $575 from $510 at Needham
Premium
The Fly
Praxis Precision price target raised to $575 from $510 at Needham
1M ago
PRAX
Praxis Wins FDA Breakthrough Status for Elsunersen Epilepsy Drug
Premium
Company Announcements
Praxis Wins FDA Breakthrough Status for Elsunersen Epilepsy Drug
2M ago
8K
PRAX
Praxis Precision granted breakthrough therapy designation for elsunersen
PremiumThe Fly
Praxis Precision granted breakthrough therapy designation for elsunersen
2M ago
PRAX
Praxis Precision initiated with an Outperform at RBC Capital
PremiumThe Fly
Praxis Precision initiated with an Outperform at RBC Capital
2M ago
PRAX
Praxis Precision Medicines Shareholders Back Directors and Governance
PremiumCompany Announcements
Praxis Precision Medicines Shareholders Back Directors and Governance
2M ago
8K
PRAX
Praxis Precision management to meet with Piper Sandler
PremiumThe Fly
Praxis Precision management to meet with Piper Sandler
2M ago
PRAX
Praxis Precision falls -15.4%
PremiumThe FlyPraxis Precision falls -15.4%
2M ago
PRAX
Praxis Precision price target lowered to $616 from $715 at Truist
Premium
The Fly
Praxis Precision price target lowered to $616 from $715 at Truist
2M ago
PRAX
Praxis Precision price target lowered to $650 from $750 at Oppenheimer
Premium
The Fly
Praxis Precision price target lowered to $650 from $750 at Oppenheimer
2M ago
PRAX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >